Andrew’s patent practice is principally in the pharmaceutical and chemical fields. He has extensive experience in securing patent protection for pharmaceuticals and specialises in drafting and prosecuting patent applications covering new chemical entities, salts, polymorphs, formulations (including advanced drug delivery technologies), manufacturing processes, medical uses, and medical devices. Outside of the pharmaceutical field, Andrew’s practice encompasses agrochemicals, polymer chemistry, petroleum additives, catalytic compositions, separation chemistry, adhesive technologies and biosensors.
Andrew acts for a diverse range of clients, including international corporations, universities, start-up companies and associate patent attorney firms based outside of the UK.
He commenced his patent career in private practice before joining the in-house patent department of a major multi-national pharmaceutical company in June 2004. As an in-house attorney, Andrew was responsible for the patent portfolios relating to a number of high priority drug development projects, as well as conducting IP due diligence evaluations to support in-licensing activities. Andrew returned to private practice in November 2008 when he joined the Manchester office of HGF as a Partner.
Andrew draws on both his private practice and in-house experience to provide commercially-focused advice to his clients in relation to all patent matters, including patent portfolio management, enforcing patent rights, challenging third party patent rights, providing infringement and validity opinions, and conducting due diligence evaluations to support licensing and acquisition deals. Andrew also has considerable experience in representing clients in opposition and appeal proceedings at the European Patent Office.
The development and evaluation of microparticulate formulations for DNA immunisation
Postgraduate Certificate in Intellectual Property Law
Andrew is listed in the IAM Strategy 300 as a leading IP strategist
Andrew is listed in the IAM Patent 1000 as a leading IP attorney in his field.
Andrew is listed as a MIP Star.
November 21st 2023
September 22nd 2022
October 7th 2021
Andrew mentors and contributes to the professional training of Trainee Patent Attorneys within HGF, as well as mentoring and training of IP and technology transfer professionals in other organisations.
Order of the classifications listed on the front of a patent and why it matters? On 1 June 2023, ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE lodged a statement of revocation of …Read article
HGF is pleased to invite you to our upcoming German-language webinar in cooperation with the BVIZ on “In- and Out-licensing of Technologies” on 16th of November 2023. The webinar will …Event details
The advent of commercial launch capabilities has opened up space as a unique frontier for innovation. However, in space, any acts of patent infringement almost always go unseen. Thus, it’s …Read article
Any communications sent from the EPO on or after 1 November 2023 will no longer have the “ten day rule” applied to them. This means that communications are deemed to …Read article
HGF is pleased to invite you to our upcoming German-language seminar on “In- and Out-licensing of Technologies” in Salzburg and Dresden. The seminar will offer you the opportunity to gain …Event details
Bioforward, OBN’s ‘Roadmap for Growth’ Life Sciences event is set to take place at The King’s Centre in Oxford on Tuesday 26th September 2023. This event is designed to provide the support, skills, know-how …Event details
The integration of artificial intelligence (AI) into healthcare has ushered in a new era of personalised medicine, promising more effective and tailored treatments for patients. Traditional medical approaches often adopt …Read article
Time: 14.00 – 15.00 UTC HGF Patent Director, Dr Janine Swarbrick will be speaking on the upcoming Lexology webinar: Across Continents: Exploring Common Ground and Contrasts in Patenting Software Inventions …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.